PD-L1 testing in urothelial bladder cancer: essentials of clinical practice

2020 ◽  
Author(s):  
Mathieu Rouanne ◽  
Camélia Radulescu ◽  
Julien Adam ◽  
Yves Allory
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder

scholarly journals Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions

2019 ◽  
Vol 15 (8) ◽  
pp. 421-428 ◽  
Author(s):  
Nataliya Mar ◽  
Farshid Dayyani
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Molecular Mechanisms ◽  
Checkpoint Inhibitors ◽  
Response To Treatment ◽  
Urothelial Bladder Cancer ◽  
Platinum Based Chemotherapy ◽  
Urothelial Bladder ◽  
Muscle Invasive ◽  
Gray Areas

Management of urothelial bladder cancer has historically been challenging as a result of a limited grasp of disease biology and few available systemic therapy options, mainly consisting of platinum-based chemotherapy. Improved understanding of molecular mechanisms underlying pathogenesis of muscle-invasive bladder cancer as well as their correlation with tumor behavior and response to treatment has emerged over the past few years. Remarkable therapeutic advances have been made with the introduction of checkpoint inhibitors, which have changed the course of this disease. Multiple agents with novel mechanisms of action are also actively being explored in ongoing clinical trials. These advances are exciting but may prove challenging in terms of how to apply this constantly evolving plethora of data to actual patients. This review addresses the gray areas and challenging questions that frequently arise in clinical practice.

scholarly journals Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

2020 ◽  
Vol 18 (3) ◽  
pp. 329-354 ◽  
Author(s):  
Thomas W. Flaig ◽  
Philippe E. Spiess ◽  
Neeraj Agarwal ◽  
Rick Bangs ◽  
Stephen A. Boorjian ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Clinical Practice ◽  
Urothelial Carcinoma ◽  
Clinical Practice Guidelines ◽  
Practice Guidelines ◽  
Urothelial Bladder Cancer ◽  
Nccn Guidelines ◽  
Urothelial Bladder ◽  
Biomarker Testing ◽  
Muscle Invasive

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice

2014 ◽  
Vol 32 (7) ◽  
pp. 1078-1087 ◽  
Author(s):  
Bas W.G. van Rhijn ◽  
James W. Catto ◽  
Peter J. Goebell ◽  
Ruth Knüchel ◽  
Shahrokh F. Shariat ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Markers ◽  
Clinical Practice ◽  
Cancer Prognosis ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder

scholarly journals Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations

2018 ◽  
pp. 1-7 ◽  
Author(s):  
Randy F. Sweis ◽  
Brian Heiss ◽  
Jeremy Segal ◽  
Lauren Ritterhouse ◽  
Sabah Kadri ◽  
...  
Keyword(s):  
Dna Damage ◽  
Bladder Cancer ◽  
Dna Damage Response ◽  
Gene Mutations ◽  
Clinical Activity ◽  
Urothelial Bladder Cancer ◽  
Response Gene ◽  
Damage Response ◽  
Urothelial Bladder

scholarly journals Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer

2018 ◽  
Vol 4 (1) ◽  
pp. 137-137
Author(s):  
Madhuri Koti ◽  
Amanda Shuo Xu ◽  
Kevin Yi Mi Ren ◽  
Kash Visram ◽  
Runhan Ren ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumour Stage ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Tertiary Lymphoid Structures ◽  
Lymphoid Structures

Recent advances in neoadjuvant immunotherapy for urothelial bladder cancer: what to expect in the near future

2021 ◽  
pp. 102142
Author(s):  
M. Rey-Cárdenas ◽  
F. Guerrero-Ramos ◽  
A. Gómez de Liaño Lista ◽  
A. Carretero-González ◽  
H. Bote ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Bladder Cancer ◽  
Recent Advances ◽  
Neoadjuvant Immunotherapy ◽  
Urothelial Bladder ◽  
Near Future

scholarly journals Expression of Vitamin D Receptor (VDR) Positively Correlates with Survival of Urothelial Bladder Cancer Patients

2015 ◽  
Vol 16 (10) ◽  
pp. 24369-24386 ◽  
Author(s):  
Wojciech Jóźwicki ◽  
Anna Brożyna ◽  
Jerzy Siekiera ◽  
Andrzej Slominski
Keyword(s):  
Vitamin D ◽  
Bladder Cancer ◽  
Cancer Patients ◽  
Vitamin D Receptor ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder

scholarly journals Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Karolina Boman ◽  
Gustav Andersson ◽  
Christoffer Wennersten ◽  
Björn Nodin ◽  
Göran Ahlgren ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Rna Binding ◽  
Prognostic Biomarkers ◽  
Binding Motif ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder
Sign in / Sign up

Export Citation Format

Share Document